Patents by Inventor Sarah Wright

Sarah Wright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of perlecan domain V in treating amyloidogenic disease
    Patent number: 9358273
    Abstract: The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of A? peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: June 7, 2016
    Assignee: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Gregory J. Bix, Sarah Wright, Irene Griswold-Prenner
  • USE OF PERLECAN DOMAIN V IN TREATING AMYLOIDOGENIC DISEASE
    Publication number: 20130036481
    Abstract: The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of A? peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.
    Type: Application
    Filed: January 6, 2011
    Publication date: February 7, 2013
    Applicant: THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Gregory J. Bix, Sarah Wright, Irene Griswold-Prenner
  • Methods of inhibiting amyloid toxicity
    Patent number: 7901683
    Abstract: The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: March 8, 2011
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Irene Griswold-Prenner, Sarah Wright, Theodore Yednock, Russell Rydel
  • SIGNALING INTERMEDIATES IN AN IN VITRO MODEL OF ALZHEIMER'S DISEASE
    Publication number: 20100303824
    Abstract: The invention provides a novel human protein, FISH adaptor protein, involved in amyloid ?-protein-mediated cell death. Also provided are methods for modulating amyloid ?-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein.
    Type: Application
    Filed: January 26, 2010
    Publication date: December 2, 2010
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: NIKOLAY MALININ, MAILE SKOMP, SARAH WRIGHT, IRENE GRISWOLD-PRENNER
  • Methods of treating cognitive impairment
    Patent number: 7829087
    Abstract: Methods and compositions for suppressing amyloid-mediated inhibition of long-term potentiation (LTP) are provided.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: November 9, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Sarah Wright, Irene Griswold-Prenner
  • Signaling intermediates in an in vitro model of Alzheimer's disease
    Patent number: 7674597
    Abstract: The invention provides a novel human protein, FISH adaptor protein, involved in amyloid ?-protein-mediated cell death. Also provided are methods for modulating amyloid ?-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: March 9, 2010
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Nikolay Malinin, Maile Skomp, Sarah Wright, Irene Griswold-Prenner
  • METHODS OF INHIBITING AMYLOID TOXICITY
    Publication number: 20090220505
    Abstract: The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.
    Type: Application
    Filed: December 16, 2008
    Publication date: September 3, 2009
    Inventors: IRENE GRISWOLD-PRENNER, SARAH WRIGHT, THEODORE YEDNOCK, RUSSELL RYDEL
  • Methods of inhibiting amyloid toxicity
    Patent number: 7517525
    Abstract: The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: April 14, 2009
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Irene Griswald Prenner, Sarah Wright, Theodore Yednock, Russell Rydel
  • Methods of suppressing LTP inhibition
    Publication number: 20080193444
    Abstract: Methods and compositions for suppressing amyloid-mediated inhibition of long-term potentiation (LTP) are provided.
    Type: Application
    Filed: March 21, 2007
    Publication date: August 14, 2008
    Inventors: Sarah Wright, Irene Griswold-Prenner, Qinwen Wang, Igor Klyubin, Michael Rowan, Roger Anwyl
  • Signaling intermediates in an in vitro model of Alzheimer's disease
    Publication number: 20060159674
    Abstract: The invention provides a novel human protein, FISH adaptor protein, involved in amyloid ?-protein-mediated cell death. Also provided are methods for modulating amyloid ?-protein-mediated cell death using agents that interfere with the activity of FISH adaptor protein.
    Type: Application
    Filed: August 1, 2005
    Publication date: July 20, 2006
    Inventors: Nikolay Malinin, Maile Skomp, Sarah Wright, Irene Griswold-Prenner
  • Methods of inhibiting amyloid toxicity
    Publication number: 20030109435
    Abstract: The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.
    Type: Application
    Filed: July 9, 2002
    Publication date: June 12, 2003
    Inventors: Irene Griswald Prenner, Sarah Wright, Theodore Yednock, Russell Rydel